AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6209488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 5 mg i.v.
Number of subjects: 19
Study 6209488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 10 mg i.v.
Number of subjects: 19
Study 6209488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 2.5 mg i.v. after beta-blockade with propranolol
Number of subjects: 19
Study 31180258 — intervention group
Group type: EXPERIMENTAL
Intervention: FCL plus topical SC‐CM
Number of subjects: 33
Study 31180258 — intervention group
Group type: EXPERIMENTAL
Intervention: FCL plus topical PRP
Number of subjects: 33
Study 31180258 — intervention group
Group type: EXPERIMENTAL
Intervention: FCL/PRP and FCL/SC‐CM
Number of subjects: 33
Study 31180258 — intervention group
Group type: COMPARATOR
Intervention: FCL only
Number of subjects: 33
Study 31211326 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 454
Study 31211326 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 454
Study 29032362 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on non-ischaemia-related independent prognostic predictors
Number of subjects: 14279
Study 29032362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemia at stress echocardiography
Number of subjects: 14279
Study 27302306 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive discussion groups (12 weekly 90-min sessions)
Number of subjects: 81
Study 27302306 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 81
Study 25419597 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral, delayed-release mesalamine (27-71 mg · g(‐1) · day(‐1))
Number of subjects: 81
Study 25419597 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral, delayed-release mesalamine (53-118 mg · g(‐1) · day(‐1))
Number of subjects: 81
Study 25419597 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral, delayed-release mesalamine
Number of subjects: 81
Study 25419597 — intervention group
Group type: COMPARATOR
Intervention: High-dose oral, delayed-release mesalamine
Number of subjects: 81
Study 22449453 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial urinary sphincter (AUS), AMS-800 placement
Number of subjects: 12
Study 21314086 — intervention group
Group type: EXPERIMENTAL
Intervention: LED LCU (LEDMAX 4, Hilux, Kulzer comp.) for 10 seconds
Number of subjects: 120
Study 21314086 — intervention group
Group type: EXPERIMENTAL
Intervention: LED LCU (LEDMAX 4, Hilux, Kulzer comp.) for 20 seconds
Number of subjects: 120
Study 21314086 — intervention group
Group type: EXPERIMENTAL
Intervention: LED LCU (LEDMAX 4, Hilux, Kulzer comp.) for 40 seconds
Number of subjects: 120
Study 21314086 — intervention group
Group type: COMPARATOR
Intervention: Conventional halogen-based LCU (Hilux unit, Heraeus Kulzer comp.) for 40 seconds
Number of subjects: 120
Study 18379511 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (atarax) as a substitutive therapy after immediate withdrawal of BDT
Number of subjects: 59
Study 18379511 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy during continuous withdrawal of BDT over 14 days
Number of subjects: 59
Study 18379511 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (atarax)
Number of subjects: 59
Study 16087407 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured nurse-led intervention program (1-day group education followed by extended nurse follow-up and counseling)
Number of subjects: 114
Study 16087407 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured nurse-led intervention program
Number of subjects: 114
Study 12161494 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH stimulation test
Number of subjects: 11
Study 10385768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous continuous dobutamine
Number of subjects: 471
Study 10385768 — intervention group
Group type: COMPARATOR
Intervention: No dobutamine
Number of subjects: 471
Study 7475768 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for H pylori serology
Number of subjects: 183
Study 7475768 — intervention group
Group type: COMPARATOR
Intervention: Non-endoscoped screen-negative patients
Number of subjects: 183
Study 2275270 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzonal
Number of subjects: 0
Study 2275270 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 0
Study 31682891 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 18
Study 31452486 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual format of cognitive-behavioral intervention
Number of subjects: 360
Study 31452486 — intervention group
Group type: COMPARATOR
Intervention: Group format of cognitive-behavioral intervention
Number of subjects: 360
Study 29129192 — intervention group
Group type: EXPERIMENTAL
Intervention: MI+HealthCall-S
Number of subjects: 42
Study 29129192 — intervention group
Group type: COMPARATOR
Intervention: MI-only
Number of subjects: 42
Study 26293185 — intervention group
Group type: EXPERIMENTAL
Intervention: Degradable PDLLA‐membrane for sinus membrane elevation
Number of subjects: 5
Study 26293185 — intervention group
Group type: COMPARATOR
Intervention: Mixture of autogenous and xenogenous bone for conventional sinus floor augmentation
Number of subjects: 5
Study 26293185 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (experimental and control)
Number of subjects: 5
Study 23235199 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsified fat
Number of subjects: 18
Study 21797917 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGDF‐5/β‐TCP with a 3‐month healing period
Number of subjects: 30
Study 21797917 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGDF‐5/β‐TCP with a 4‐month healing period
Number of subjects: 30
Study 21797917 — intervention group
Group type: COMPARATOR
Intervention: β‐TCP and autogenous bone (β‐TCP/AB) with a 4‐month healing period
Number of subjects: 30
Study 20394247 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg/kg
Number of subjects: 60
Study 20394247 — intervention group
Group type: COMPARATOR
Intervention: saline 3 ml
Number of subjects: 60
Study 17217362 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiatherogenic diet low in saturated fat and cholesterol from gestational week 17‐20 to birth
Number of subjects: 290
Study 17217362 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 290
Study 15961699 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological (PHYS) noninvasive Pressure Support Ventilation (nPSV)
Number of subjects: 9
Study 15961699 — intervention group
Group type: COMPARATOR
Intervention: Usual (US) noninvasive Pressure Support Ventilation (nPSV)
Number of subjects: 9
Study 15961699 — intervention group
Group type: EXPERIMENTAL
Intervention: nPSV (both settings)
Number of subjects: 9
Study 12190807 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol plus magnesium (TM)
Number of subjects: 66
Study 12190807 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol plus ketamine (TK)
Number of subjects: 66
Study 12190807 — intervention group
Group type: COMPARATOR
Intervention: Tramadol alone (T)
Number of subjects: 66
Study 7651682 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized anesthetic solution
Number of subjects: 21
Study 7651682 — intervention group
Group type: COMPARATOR
Intervention: Fixed-volume alkalinization
Number of subjects: 21
Study 7651682 — intervention group
Group type: COMPARATOR
Intervention: Nadbath injection
Number of subjects: 21
Study 2523264 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (200 mg)
Number of subjects: 6
Study 2523264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 349379 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent quality assurance (CQA)
Number of subjects: 5604
Study 349379 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 5604
Study 31712214 — intervention group
Group type: EXPERIMENTAL
Intervention: RV521 350 mg
Number of subjects: 66
Study 31712214 — intervention group
Group type: EXPERIMENTAL
Intervention: RV521 200 mg
Number of subjects: 66
Study 31712214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31690775 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically instrumented blood lead
Number of subjects: 361194
Study 28727702 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of triamcinolone and lidocaine
Number of subjects: 100
Study 28727702 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (oral antivirals and analgesics)
Number of subjects: 100
Study 28727702 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 26557618 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser technique
Number of subjects: 70
Study 26557618 — intervention group
Group type: COMPARATOR
Intervention: Scalpel technique
Number of subjects: 70
Study 23698171 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) by dentists
Number of subjects: 1629
Study 23698171 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) by auxiliaries
Number of subjects: 1629
Study 23698171 — intervention group
Group type: COMPARATOR
Intervention: Amalgam by dentists
Number of subjects: 1629
Study 23698171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of ART
Number of subjects: 1629
Study 21744945 — intervention group
Group type: EXPERIMENTAL
Intervention: Online CBT (NET)
Number of subjects: 115
Study 21744945 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based CBT (CLIN)
Number of subjects: 115
Study 21744945 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 115
Study 19188683 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial-targeted antioxidant treatment in rats
Number of subjects: 0
Study 19188683 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically engineered overexpression of catalase in mitochondria of muscle in mice
Number of subjects: 0
Study 19188683 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 0
Study 17211305 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg of isobaric bupivacaine with 20 microgr fentanyl
Number of subjects: 40
Study 17211305 — intervention group
Group type: COMPARATOR
Intervention: 13.5 mg of standardized isobaric 0.5% bupivacaine
Number of subjects: 40
Study 12776641 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ondansetron (4 mg)
Number of subjects: 100
Study 12776641 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isopropyl alcohol (70%)
Number of subjects: 100
Study 10671913 — intervention group
Group type: EXPERIMENTAL
Intervention: Health authority/pharmaceutical company collaborative intervention
Number of subjects: 140
Study 10671913 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 140
Study 9483987 — intervention group
Group type: EXPERIMENTAL
Intervention: Naclof (sodium diclofenac) eye drops
Number of subjects: 40
Study 9483987 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Naclof)
Number of subjects: 40
Study 8404196 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency ventilation (HFV)
Number of subjects: 12
Study 8404196 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 12
Study 3007219 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (open biopsy, resection, excision)
Number of subjects: 43
Study 3007219 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete removal of the tumor (surgery)
Number of subjects: 43
Study 3007219 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 43
Study 3007219 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall surgical treatment
Number of subjects: 43
Study 3007219 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Number of subjects: 43
Study 3007219 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative chemotherapy
Number of subjects: 43
Study 31939316 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (E2)
Number of subjects: 1512
Study 31939316 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum E2 levels
Number of subjects: 1512
Study 29885694 — intervention group
Group type: EXPERIMENTAL
Intervention: MVD with concomitant non-IRA CTO (n = 74)
Number of subjects: 791
Study 29885694 — intervention group
Group type: COMPARATOR
Intervention: MVD without CTO (n = 372)
Number of subjects: 791
Study 29885694 — intervention group
Group type: COMPARATOR
Intervention: SVD (n = 345)
Number of subjects: 791
Study 26287652 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treatment
Number of subjects: 18
Study 26287652 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based treatment
Number of subjects: 18
Study 24824014 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA) meal (macadamia nut oil)
Number of subjects: 34
Study 24824014 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 34
Study 23394509 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled corticosteroids (ICSs) at doses of two, four, or eight times their maintenance ICS dose for 12 days
Number of subjects: 197
Study 23394509 — intervention group
Group type: COMPARATOR
Intervention: Doubling the maintenance dose of ICS
Number of subjects: 197
Study 20881507 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training at 80% of 1-repetition maximum (1RM) for 4 weeks
Number of subjects: 23
Study 20881507 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study 18395165 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 27
Study 18395165 — intervention group
Group type: COMPARATOR
Intervention: Statin-fibrate therapy (control)
Number of subjects: 27
Study 18395165 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 27
Study 16371630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 1441
Study 16371630 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1441
Study 12645393 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/die for six months)
Number of subjects: 20
Study 12645393 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 9583927 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine 12 mg/kg/day for 21 days
Number of subjects: 120
Study 9583927 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine 16 mg/kg/day for 21 days
Number of subjects: 120
Study 9583927 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine 20 mg/kg/day for 21 days
Number of subjects: 120
Study 9583927 — intervention group
Group type: COMPARATOR
Intervention: Sodium stibogluconate 20 mg/kg/day for 30 days
Number of subjects: 120
Study 9583927 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine (16 and 20 mg/kg/day)
Number of subjects: 120
Study 9583927 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 120
Study 7712676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 12
Study 7712676 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 12
Study 7712676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2559525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsy (BMB)
Number of subjects: 71
Study 413794 — intervention group
Group type: EXPERIMENTAL
Intervention: Gnotobiotic care
Number of subjects: 0
Study 413794 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28598897 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Trigger Tool (GTT) methodology implementation with continuous training and specific review rules.
Number of subjects: 1320
Study 28598897 — intervention group
Group type: COMPARATOR
Intervention: First round interrater reliability assessment before intervention.
Number of subjects: 1320
Study 31617395 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise and education programme
Number of subjects: 154
Study 30256277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (daily practice for 21 days)
Number of subjects: 90
Study 27343788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheniramine
Number of subjects: 120
Study 27343788 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 120
Study 27343788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22647558 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional SDM training program 'Fit for SDM'
Number of subjects: 6
Study 22647558 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the training content
Number of subjects: 6
Study 22647558 — intervention group
Group type: COMPARATOR
Intervention: Training program
Number of subjects: 6
Study 20559255 — intervention group
Group type: EXPERIMENTAL
Intervention: Viferon gel (0.5 ml, 4-5 times daily)
Number of subjects: 90
Study 17572116 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenith endograft
Number of subjects: 648
Study 17572116 — intervention group
Group type: COMPARATOR
Intervention: Talent endograft
Number of subjects: 648
Study 15713907 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 807
Study 15713907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin A supplementation)
Number of subjects: 807
Study 12111469 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl washout
Number of subjects: 11
Study 10586171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry concentrate
Number of subjects: 15
Study 10586171 — intervention group
Group type: COMPARATOR
Intervention: Placebo concentrate
Number of subjects: 15
Study 8598085 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm training for 6 weeks
Number of subjects: 22
Study 8598085 — intervention group
Group type: COMPARATOR
Intervention: Dynamic handgrip and posthandgrip regional circulatory occlusion (PH-RCO)
Number of subjects: 22
Study 1874208 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 30 ng kg‐1 min‐1
Number of subjects: 15
Study 1874208 — intervention group
Group type: COMPARATOR
Intervention: Control (no PGE1 administration)
Number of subjects: 15
Study 6218964 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA) administered on cycle day 5
Number of subjects: 49
Study 6218964 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA) administered on cycle day 7
Number of subjects: 49
Study 6218964 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA) administered on cycle day 9
Number of subjects: 49
Study 6218964 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA) administered on cycle day 11
Number of subjects: 49
Study 31884492 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS-supported multimodal balance training
Number of subjects: 154
Study 31884492 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular multimodal balance training
Number of subjects: 154
Study 31272277 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-MOT combined with a decision-making task
Number of subjects: 57
Study 31272277 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidated 3D-MOT later combined with a decision-making task
Number of subjects: 57
Study 31272277 — intervention group
Group type: COMPARATOR
Intervention: Isolated decision-making task
Number of subjects: 57
Study 31272277 — intervention group
Group type: COMPARATOR
Intervention: Isolated 3D-MOT
Number of subjects: 57
Study 26959873 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal countermovement jumps on two force platforms (1000 Hz) linked to a nine camera infrared motion capture system (500 Hz)
Number of subjects: 18
Study 26959873 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation and conditioning exercises targeting frontal and transverse plane movement
Number of subjects: 18
Study 25500669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapor ablation therapy targeting the most diseased segments of the lung, specific dosage and duration not mentioned.
Number of subjects: 0
Study 25500669 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental targeting using the segmental heterogeneity index for quantifying emphysema severity.
Number of subjects: 0
Study 24867906 — intervention group
Group type: COMPARATOR
Intervention: Exercises only (Control Group 1, n=60)
Number of subjects: 121
Study 24867906 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school program and exercises (Group 2, n=61)
Number of subjects: 121
Study 22840278 — intervention group
Group type: EXPERIMENTAL
Intervention: C+P (behavioral counseling and education followed by monthly phone calls for 6 months)
Number of subjects: 1155
Study 22840278 — intervention group
Group type: COMPARATOR
Intervention: C (behavioral counseling and education at baseline)
Number of subjects: 1155
Study 22840278 — intervention group
Group type: COMPARATOR
Intervention: S (standard care)
Number of subjects: 1155
Study 22840278 — intervention group
Group type: EXPERIMENTAL
Intervention: C+P
Number of subjects: 1155
Study 22840278 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 1155
Study 22840278 — intervention group
Group type: COMPARATOR
Intervention: S
Number of subjects: 1155
Study 20600678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonal melodies
Number of subjects: 10
Study 20600678 — intervention group
Group type: COMPARATOR
Intervention: Random notes
Number of subjects: 10
Study 20600678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonal melodies and random notes
Number of subjects: 10
Study 17664469 — intervention group
Group type: EXPERIMENTAL
Intervention: ECF (epirubicin 50 mg/m(2) on day 1, cisplatin 60 mg/m(2) on day 1, and fluorouracil 200 mg/m(2)/d on days 1 to 21)
Number of subjects: 119
Study 17664469 — intervention group
Group type: EXPERIMENTAL
Intervention: TC (docetaxel initially 85 mg/m(2) on day 1, later reduced to 75 mg/m(2), and cisplatin 75 mg/m(2) on day 1)
Number of subjects: 119